Objectives: Anti-TNFs are the most commonly used biologics in rheumatologic and dermatologic immune diseases in the UK with three of these drugs ranking in the top drug spends of NICE. The biosimilars' introduction as a treatment option is thought to be an opportunity to achieve cost savings within the healthcare environment. The study objective was to assess the possible budget impact of introducing Benepali®, an etanercept biosimilar, within the UK for all licensed adult etanercept indications. Methods: A budget-impact model was used to estimate the cost saving potential of introducing Benepali vs Enbrel®, the etanercept reference product, in the UK over a three-year time horizon from the regional payer's perspective. Current etanercept treated population has been estimated through IMS sales data and the population was assumed to remain constant during the 3-year horizon. Two scenarios were developed with two different Benepali adoptions: a) a moderate uptake: 15%, 30%, 45% and b) a rapid uptake: 20%, 40%, 60% at year 1, 2, 3 respectively. Prices for Benepali and Enbrel were obtained from published sources and 5% price erosion per year was modelled for both products. An average nurse salary was assumed to be mid-point (band 6) on current payscales (March 2016). Results: Benepali introduction into the biologic treatment setting in the UK resulted in projected budget savings over the three-year horizon of: £14.2m and £18.9m in the moderate and rapid uptake scenario respectively. This could generate savings equivalent to an additional 1,781 to 2,374 patient-years. These savings are equivalent to salaries of additional 468-623 nurses for NHS England. Conclusions: Benepali introduction represents substantial cost-saving opportunities for all studied regions. Regional policies toward biosimilars influence their adoption thus impacting saving potential. Collaborative (e.g. gain-sharing) agreement at regional levels between payers and prescribers may create more cost-efficient use of medicines whilst releasing investment opportunities within clinical pathways.
Psachoulia, E., & Negrini, C. (2016). Evaluation of The Cost Saving Potential of Introducing Benepali®, An Etanercept Biosimilar, For The Treatment of All Licensed Adult Etanercept Indications In Three Regions In Italy. Value in Health, 19(7), A534. https://doi.org/10.1016/j.jval.2016.09.1090